CAN ANGIOTENSIN-CONVERTING ENZYME INHIBITORS REDUCE STROKE?
Angiotensin-converting enzyme inhibitors reduce total mortality, stroke, and major cardiovascular end points in patients who have coronary artery disease and no left ventricular systolic dysfunction or heart failure, according to a study published in the April 10 Archives of Internal Medicine. Nicolas Danchin, MD, and colleagues screened 1,146 publications and included seven, for a combined total of 33,960 patients followed up for a mean of 4.4 years. Five trials included only patients with documented coronary artery disease. One trial included patients with documented coronary artery disease (80%) or patients who had diabetes mellitus and one or more additional risk factors, and the remaining trial included patients who had coronary artery disease, a history of transient ischemic attack, or intermittent claudication. Results showed that treatment with angiotensin-converting enzyme inhibitors decreased overall mortality, cardiovascular mortality, myocardial infarction, and stroke. In a
Related Questions
- Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
- are there differences between structurally different angiotensin-converting enzyme inhibitors?
- Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?
